Home/Filings/4/0000899243-20-032448
4//SEC Filing

HUTCHISON PATRICK 4

Accession 0000899243-20-032448

CIK 0000875622other

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 9:45 AM ET

Size

6.0 KB

Accession

0000899243-20-032448

Insider Transaction Report

Form 4
Period: 2020-12-02
Hutchison Patrick
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-12-02$32.29/sh10,000$322,9000 total
    Exercise: $56.21Exp: 2030-01-06Common Stock (10,000 underlying)
Footnotes (1)
  • [F1]Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (January 6, 2020), were canceled in exchange for a cash payment of $322,900.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.

Issuer

BIOSPECIFICS TECHNOLOGIES CORP

CIK 0000875622

Entity typeother

Related Parties

1
  • filerCIK 0001673870

Filing Metadata

Form type
4
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 9:45 AM ET
Size
6.0 KB